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We describe scalable and cost-efficient production of full length, His-tagged SARS-
CoV-2 spike glycoprotein trimer by CHO cells that can be used to detect SARS-CoV-
2 antibodies in patient sera at high specificity and sensitivity. Transient production of 
spike in both HEK and CHO cells mediated by PEI was increased significantly (up to 
10.9-fold) by a reduction in culture temperature to 32ºC to permit extended duration 
cultures. Based on these data GS-CHO pools stably producing spike trimer under the 
control of a strong synthetic promoter were cultured in hypothermic conditions with 
combinations of bioactive small molecules to increase yield of purified spike product 
4.9-fold to 53 mg/L. Purification of recombinant spike by Ni-chelate affinity 
chromatography initially yielded a variety of co-eluting protein impurities identified 
as host cell derived by mass spectrometry, which were separated from spike trimer 
using a modified imidazole gradient elution. Purified CHO spike trimer antigen was 
used in ELISA format to detect IgG antibodies against SARS-CoV-2 in sera from 
patient cohorts previously tested for viral infection by PCR, including those who had 
displayed COVID-19 symptoms. The antibody assay, validated to ISO 15189 Medical 
Laboratories standards, exhibited a specificity of 100% and sensitivity of 92.3%. Our 
data show that CHO cells are a suitable host for the production of larger quantities of 
recombinant SARS-CoV-2 trimer which can be used as antigen for mass serological 
testing. 
Keywords: bioproduction; CHO cells; SARS-CoV-2; COVID-19; spike trimer; 
serological assay 
Immune response represents the first line of defense against severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection that has caused the coronavirus 
 














disease 2019 (COVID-19) pandemic. The spike glycoprotein that protrudes from the 
surface of the virus is highly immunogenic with the receptor-binding domain (RBD) 
being the target of many neutralizing antibodies (Yuan et al., 2020). Utilizing a 
stabilized version of the full-length SARS-CoV-2 spike protein, a very robust and 
accurate serological enzyme-linked immunosorbent assay (ELISA) for antibodies in 
patient sera has recently been developed (Amanat et al., 2020) and approved for use 
by the US FDA. However, very low production titers (1–2 mg/L) of the spike trimer 
were reported using the human embryonic kidney (HEK) Expi293 Expression system 
(Esposito et al., 2020; see Supplementary Figure S1), therefore effectively limiting its 
widespread utilization as a preferred antigen in serological assays for COVID-19. The 
low production titer is not surprising considering that the SARS-CoV-2 spike is a 
large homotrimer (~670 kDa) with 22 N-linked glycosylation sites per monomer 
(Watanabe et al., 2020). In this work, using improved vector engineering and 
production process strategies we describe the development of a stable recombinant 
spike manufacturing platform utilizing Chinese hamster ovary (CHO) cells as a 
preferred production host. Transient expression was initially employed to fast-track 
production of recombinant protein to enable biophysical analyses and early clinical 
evaluation in serological assays, as well as to evaluate product manufacturability and 
refine production process and purification conditions.  
We have previously shown that for difficult-to-express (DTE) proteins, 
transient production processes need to be tailored to negate the protein-specific 
negative effects of recombinant gene overexpression in host cells (e.g., unfolded 
protein response (UPR) induction, limited cell-specific productivity (qP); Johari et al., 
2015). Using the plasmid construct from the Krammer Laboratory (see Materials and 
Methods for details), HEK Expi293F and CHO-S cells were transiently transfected 
 














with the CAG-driven expression plasmid using PEI at an optimal gene dosage for 
spike production in both cases (data not shown). Further, we utilized a mild 
hypothermic condition, an effective process engineering intervention for production 
of DTE proteins (e.g., Estes et al., 2015; Johari et al., 2015) and to extend culture 
longevity (Figure 1A,B). As shown in Figure 1C, the qP of HEK cells increased 2.4-
fold from 0.20 pg/cell/day to 0.48 pg/cell/day when the culture temperature was 
lowered from 37°C to 32°C. Additionally, the prolonged batch culture duration at 
32°C enabled a 4.1-fold increase in titer, yielding 10.2 mg/L of purified spike. Greater 
enhancement was observed with CHO cells where mild hypothermia resulted in an 
8.5-fold higher qP than that at 37°C, and a further increase in titer (10.9-fold, 5.4 
mg/L) was obtained via increased cell accumulation. We anticipate that improved 
CHO systems (e.g., ExpiCHO-S cell line and ExpiCHO medium) as well as co-
expression of genetic effectors and chemical chaperone addition (Cartwright et al., 
2020; Johari et al., 2015) would significantly increase spike transient production in 
CHO cells. The CHO-derived spike exhibited a monomeric molecular mass of ~200 
kDa by SDS-PAGE (Figure 1D) and a trimeric mass of ~670 kDa was measured using 
analytical size exclusion chromatography (Supplementary Figure S2). The material 
was further validated using peptide mapping in conjunction with mass spectrometry 
analysis (Supplementary Figure S3). Critically, the preliminary COVID-19 antibody 
serological test demonstrated its suitability for the ELISA (data not shown) thus 
permitting development of CHO stable production platform. 
For DTE proteins, very low yielding transient expression systems can be an 
early indication of reduced stable production (Mason et al., 2012), where particular 
engineering strategies may be required to obtain stable cells with desirable production 
characteristics. To generate CHO cells stably expressing recombinant spike trimer, we 
 














tested two in-house CHO synthetic promoters, namely 40RPU (~90% CMV activity) 
and 100RPU (~220% CMV activity) promoters (see Brown et al., 2017; Johari et al., 
2019). Although the use of extremely strong promoters may be counterintuitive for 
DTE proteins, we reasoned that only those transfectants harboring a sub-UPR 
threshold productivity, and thus capable of proliferation would survive. Thus, if cell 
proliferation attenuation and apoptosis occur as ER functional capacity is exceeded, 
this is a condition that would directly deselect poorly performing stable transfectants. 
The promoters and spike gene were inserted into a vector construct encoding 
glutamine synthetase (driven by an SV40 promoter) and the electroporated CHO-S 
host cells were subjected to a single round of selection at 25 or 50 μM methionine 
sulfoximine (MSX), using suspension culture. After 19 days, recovered CHO cell 
populations were screened for the ability to produce spike in 3-day batch culture 
(Figure 2A). These data showed that transfectant pools derived from genetic 
constructs harboring the strong 100RPU promoter expressed recombinant spike 
whereas those using the weaker 40RPU promoter did not. More stringent selection 
conditions (50 µM MSX) yielded transfectant pools exhibiting lower productivity. 
Accordingly, CHO cell pools harboring the 100RPU promoter under 25 μM MSX 
were taken forward for the manufacturing process.  
In order to rapidly produce recombinant spike, stable transfectant pools (rather 
than clonally derived populations) were employed. Based on CHO transient process 
data (Figure 1), we tested the hypothesis that an optimal 10-day fed-batch stable 
production process could be executed at 32°C and further enhanced by chemical 
chaperone additives (e.g., Johari et al., 2015). We compared this strategy to an 
alternative approach utilizing culture temperature shift to achieve maximal cell 
density (biphasic), as well as constant 37°C as control. These data are shown in 
 














Figure 2B and C, whilst the screening data for eight small molecule chemical 
additives is shown in Supplementary Figure S4. Compared to the 37°C control 
culture, hypothermia resulted in a clear (33%) initial reduction in cell-specific 
proliferation rate over the first 5 days of culture (Figure 2B). However, the qP of the 
latter was 3.4-fold higher over control and addition of valproic acid (VPA) at Day 6 
further enhanced qP 5.1-fold, yielding 51 mg/L of spike after purification by 
immobilized metal affinity chromatography (IMAC; Figure 2C). Similar enhancement 
was observed with betaine although there was no synergistic effect when the two 
molecules were utilized together. Reduction in culture temperature after 3 days 
culture improved the integral of viable cell density (IVCD) 1.4-fold and when 
combined with VPA addition at Day 4, 53 mg/L of spike was attained after IMAC 
purification. These data demonstrate that the optimal process engineering intervention 
for recombinant spike production identified for rapid transient gene expression was 
generally translatable to the stable production process. Further, as low-level, sub-UPR 
threshold expression is likely required to permit adequate cell growth (Supplementary 
Figure S1), we reasonably expect that application of mammalian inducible expression 
technology (e.g. cumate; Poulain et al., 2017) to switch on spike production using an 
intensified biphasic culture system would be particularly useful to maximize stable 
production. 
To purify spike protein from culture supernatant, IMAC was initially 
performed using a step-elution of 250 mM imidazole according to Stadlbauer et al. 
(2020). Figure 3A shows SDS-PAGE of eluted proteins, and reveals the presence of 
protein impurities not derived from recombinant spike (Figure 3B), which were 
identified using tandem mass spectrometry as CHO host cell derived proteins (HCPs). 
Whilst all of the identified extracellular HCPs have previously been shown to be 
 














present in CHO cell culture supernatant (Park et al., 2017), HSPG in particular has 
been reported to occur in CHO cells at relatively higher level than HEK cells (Goey et 
al., 2018; Lee et al., 2016), illustrating the need for an improved purification method 
especially at high IVCDs. In order to increase recombinant spike purity, a revised 
gradient elution profile up to 250 mM imidazole was implemented. As shown in 
Figure 3C, HCPs were eluted at a lower imidazole concentration than recombinant 
spike, permitting recovery of high purity (>95%) product for use in serological assays 
(Figure 3D). 
COVID-19 antibody tests would help reveal the true scale of the pandemic in 
a population and the persistence of immunity, whether vaccines (many of which are 
based on the production of neutralizing antibodies against spike protein) designed to 
protect from infection are effective, as well as identify highly reactive human donors 
for convalescent plasma therapy. The CHO-spike anti-SARS-CoV-2 ELISA was 
developed based on the Krammer Laboratory’s assay, and validated to ISO 15189 
Medical Laboratories standards. Initially, we tested a panel of 234 negative samples 
taken pre-COVID-19 outbreak (June–August 2019) and 26 positive samples taken 
during the COVID-19 outbreak (≥15 days post-positive PCR test). ELISAs were 
performed by 1/20 dilution of the individual serum samples and the cut-off index of 
1.4 was determined using the cut-off OD value (ROC curve with 100% specificity) 
and the negative control. In this particular evaluation, the assay had an overall 
specificity of 100% and sensitivity of 92.3% as illustrated in Figure 4A. To establish 
the reproducibility of the ELISA, positive samples were tested on 5 separate assays 
over 2 days at 3 different dilutions to determine the inter-assay variations. The data 
(Figure 4B) shows that the assay performed within the standard range for precision 
with inter-assay %CV of ≤5%. To be able to interpret serosurveys correctly, the 
 














ELISA was evaluated for potential cross-reactivity from individuals with other 
medical conditions where zero positives were observed in all cases (Supplementary 
Table S1). 
Overall, our work serves as an exemplar for a development process of 
characteristically difficult-to-express spike manufacturing platform utilizing CHO 
cells. This itself is a significant and useful finding, as many DTE recombinant 
proteins cannot be produced using this industry standard production vehicle — e.g., a 
recent study reported that for over 2,200 human genes encoding secreted proteins 
expressed in CHO cells, almost 50% did not yield target protein (Uhlen et al., 2018). 
On the other hand, the spike production in HEK cells was highly dependent on the 
very expensive Expi293 medium (we note that spike production using FreeStyle 293 
medium resulted in an even lower titer (<40%); data not shown). Whilst it is 
potentially easier to produce a “monomer”, the native trimeric structure of the spike 
protein on the surface of SARS-CoV-2 is rationally more desirable for optimal 
serological assay and research. Indeed, further modifications on trimeric spike’s 
molecular architecture to improve its stability and production titers have recently been 
reported (Hsieh et al., 2020; Stuible et al., 2020; Xiong et al., 2020). Our data 
demonstrates how process and vector development could complement protein 
engineering efforts particularly where rapid product generation is required. 
With one mg of spike providing serological assays for approximately 3,500 
patient samples, the rapid, scalable transient platform was adequate for local 
population antibody tests and research studies. To enable large, constant clinical 
supply of spike, we showed that it was possible to generate CHO stable transfectants 
expressing the very complex glycoprotein, whilst high titers could be achieved via a 
 














combination of process engineering approaches designed for both high qP and cell 
biomass accumulation. The refinement of the IMAC affinity purification process 
permitted greatly enhanced purity of the CHO spike product following an extended 
10-day culture, ensuring suitability for use in serological immunity testing. The assay 
has been implemented at local hospitals with ~7,200 staff tested (as of 31 July 2020) 
which resulted in ~16% positive COVID-19 antibody detection, thus supporting the 
global effort to limit and mitigate the impact of SARS-CoV-2. Furthermore, it is 
highly likely that the cell and process engineering interventions designed for SARS-
CoV-2 spike production is generically applicable to spike from different coronavirus 
strains. 
MATERIALS AND METHODS 
Cell Cultures and Chemical Chaperones 
Expi293F cells were cultured in Expi293 Expression medium (ThermoFisher) in 
Erlenmeyer flasks maintained at 37°C, 125 rpm under 8% CO2, 85% humidity. CHO-
S clonal isolate cells (C1-80; Fernandez-Martell et al., 2018) were cultured in CD 
CHO medium (ThermoFisher) supplemented with 8 mM L-glutamine maintained at 
37°C, 140 rpm under 5% CO2, 85% humidity. Cells were seeded at 2×10
5 viable 
cells/mL and were sub-cultured every 3‒4 days. Cell viability and VCD were 
measured using the Vi-CELL XR (Beckman Coulter). The IVCD was calculated as 
follows: 
IVCD = �VCD𝑡−1+VCD𝑡2 × ∆𝑡� + IVCD𝑡−1 (Eq. 1)  
where t is the time point (day). VPA, NaBu, DMSO, glycerol, betaine, TMAO and 
proline were obtained from Sigma while TUDCA was obtained from Merck. 
 














Transient Production in HEK and CHO Cells 
pCAGGS plasmids encoding the stabilized full-length SARS-CoV-2 spike 
protein trimer (polybasic furin cleavage site removed alongside K986P and 
V987P substitutions, P1213 addition of thrombin cleavage site, T4 
trimerization domain and 6×His-tag; Amanat et al., 2020) or RBD were 
provided by the Krammer Laboratory (Icahn School of Medicine at Mount 
Sinai). The plasmids were amplified and purified using QIAGEN Plasmid Plus 
kit (Qiagen). For the optimized Expi293F transfection, cells were grown to 
1.75×106 cells/mL, centrifuged and resuspended at a density of 3.5×106 
cells/mL, followed by sequential addition of 0.85 μg of DNA and 2.55 μl of 
PEI MAX (each pre-diluted in 10 μL of 150 mM NaCl) per million cells. At 24 
h post-transfection, the cells were diluted 2× by adding fresh medium, and 
where applicable culture was shifted to 32°C. For CHO transfection, cells were 
seeded one day before transfection and grown to 1.5×106 cells/mL. For every 
1.5×106 cells, 1.3 μg of DNA and 4.55 μL of PEI MAX (each pre-diluted in 15 
μL of 150 mM NaCl) were combined and incubated at RT for 2 min before 
being added into culture. Where applicable, culture was shifted to 32°C at 4 h 
post-transfection. For fed-batch production, 5% v/v CHO CD EfficientFeed B 
was added at Days 2, 4, 6 and 8.Generation of Stable CHO Pools and Fed-
batch Production 
A stable vector containing an SV40 promoter-driven GS gene was provided by 
AstraZeneca, UK. The spike gene was cloned by PCR, inserted into the vector 
downstream of 40RPU or 100RPU synthetic promoter (Brown et al., 2017) and the 
plasmid constructs were confirmed by DNA sequencing. 10×106 cells per cuvette 
were electroporated with 7 μg linearized DNA using Cell Line Nucleofector Kit V 
system (Lonza) and transferred to a TubeSpin containing 10 mL glutamine-free 
culture medium with the addition of 25 or 50 μM MSX after 48 h. The cells were left 
to recover under suspension conditions and recovered pools were cryopreserved when 
the cell viability reached >90%. For fed-batch production, 5% v/v CHO CD 
EfficientFeed B was added at Days 2, 4, 6 and 8. 
Western Blotting 
Proteins in culture supernatant were precipitated by TCA/DOC, resuspended in LDS 
loading buffer with BME and heated to 70°C. SDS-PAGE was performed using 4–
 














12% NuPAGE Bis-tris gels and resolved proteins were transferred to nitrocellulose 
membranes by iBlot system (ThermoFisher). Membranes were blocked in 5% 
milk/TBS-T before being incubated with HRP-conjugated anti-HisTag antibody (Bio-
Rad) and visualized by enhanced chemiluminescence (ECL; ThermoFisher). 
Recombinant Protein Purification and Quantification 
Spike protein was harvested by centrifugation at 3,000×g for 20 min at 4°C and 
supernatant was filtered through a 0.22 μm filter. Protein was purified using the 
ÄKTA Pure system (Cytiva) and a 5-mL HisTrap HP column (Cytiva). The column 
was washed with 5 column volumes (CVs) of buffer B (50 mM sodium phosphate, 
300 mM NaCl, 250 mM imidazole, pH 8.0), and equilibrated with 5 CVs of buffer A 
(50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, pH 8.0). To reduce 
non-specific binding, the supernatant was adjusted to 20 mM imidazole using buffer 
B prior to sample loading. After sample loading, the column was washed in three 
steps using 5 CVs of buffer A, 5 CVs of 4.5% v/v buffer B, and 10 CVs of 9% v/v 
buffer B. Protein was eluted using 100% v/v buffer B. Eluted protein fractions were 
pooled and buffer exchanged into storage buffer (20 mM Tris, 200 mM NaCl, 10% 
v/v glycerol, pH 8.0) using a PD-10 desalting column (Cytiva). Protein was quantified 
using the Pierce Coomassie Plus (Bradford) Assay kit and bovine serum albumin for 
the calibration curve (ThermoFisher) and analyzed by reducing SDS-PAGE. An 
orthogonal quantification method was performed using an A280 measurement 
(NanoDrop OneC; ThermoFisher) with spike extinction coefficient of 428,255 M-1 cm-
1 and MW of 412.516 kDa. A complementary quantification of spike in culture 
supernatant was performed using CR3022 antibody ELISA (see below).  
 














Protein Identification by Mass Spectrometry  
All materials were supplied by ThermoFisher unless otherwise stated. Briefly, protein 
samples in 50 mM ammonium bicarbonate (ABC), 5 mM tris(2-
carboxyethyl)phosphine-HCl were reduced by incubation at 37°C for 30 min. S-
alkylation was performed by the addition of 1 µL 100 mM methyl 
methanethiosulfonate in isopropanol. For proteolytic digestion, 1.5 µL 0.2% 
ProteaseMax surfactant in 50 mM ABC and 2 µL 0.2g/L trypsin/endoproteinase Lys-
C mixture (Promega) were added followed by incubation at 37°C for 16 h. Proteolysis 
was stopped and the surfactant hydrolyzed by the addition of 0.5% trifluoroacetic acid 
(TFA). The samples were desalted using HyperSep Hypercarb solid phase extraction 
tips and dried by vacuum centrifugation. For RPLC-MS, samples in 0.5% TFA, 3% 
acetonitrile (ACN) were injected. Peptides were separated using an RSLCnano system 
with a PepSwift PS-DVB monolithic column using a gradient from 97% solvent A 
(0.1% formic acid) to 35% solvent B (0.1% formic acid, 80% ACN). Mass spectra 
were acquired on a Q Exactive HF quadrupole-Orbitrap instrument, with automated 
data dependent switching between full-MS and tandem MS/MS scans. Proteins were 
identified by converting the MS data into Mascot Generic Format (MGF) files and 
analyzed against human and Chinese hamster reference proteome databases with the 
spike glycoprotein construct sequence inserted (www.uniprot.org) using Mascot 
Daemon v.2.5.1 with Mascot server v.2.5 (Matrix Science).  
CR3022 Antibody ELISA for Spike Quantification 
96-wells were coated overnight with 100 μL of anti-SARS-CoV spike CR3022 
antibody (Absolute Antibody; 5 μg/mL in PBS) at 4°C. The coating solution was 
removed and washed twice (with 0.1% TBS-T). 100 μL of blocking solution (5% 
non-fat milk in 0.1% TBS-T) was added for 1 h and washed twice. 100 µl of sample 
 














was added and incubated for 2 h at RT. A standard curve (Supplementary Figure S5) 
was generated from serially diluted, purified and quantified CHO spike (Figure 1D) 
using CD CHO medium as diluent. Plate was washed twice before incubation with 
100 µl HRP-conjugated anti-HisTag antibody (Bio-Rad) diluted 1:500 with 5% 
milk/TBS-T for 2 h at RT. Plate was washed 3 times and 100 µl of SigmaFast OPD 
solution (Sigma) was added to each well. The reaction was allowed to proceed for 10 
minutes at RT before being stopped by the addition of 50 µl of 3 M HCl. Plate was 
read at 492 nm using a SpectraMax iD5 plate reader (Molecular Devices). 
Spike ELISA for Serological Testing  
The ELISA protocol was adapted from Stadlbauer et al. (2020) using spike protein 
with >95% purity. Microtiter plates (96-well) were coated overnight with 50 μL of 
spike per well (2 μg/mL in PBS pH 7.4) at 4°C. The coating solution was removed 
and 300 μL of blocking solution (3% non-fat milk in 0.1% PBS-T) was added for 1 h 
and washed 3 times (with 0.1% PBS-T). Samples were added at 1/20 dilution and 
incubated for 2 h at RT. Plate was washed 3 times and 100 μL of anti-human IgG 
conjugate was added to the wells and incubated for 1 h at RT. Plate was washed 3 
times and 100 μL of substrate was added and incubated in the dark for 45 minutes. 
The reaction was stopped by the addition of 50 of µl 3 M HCl and the plate was read 
at 490 nm using the Agility ELISA system (Dynex Technologies). The index value 
was calculated as follows: 
Index value =
Sample ODMean of negative controls+3SDs (Eq. 2)  
The cut-off value was calculated with 100% specificity using ROC curves of 
calculated index values. 
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LIST OF FIGURES 
Figure 1. Transient production of recombinant spike in HEK and CHO cells. HEK 
Expi293F cells and CHO-S cells were transfected with plasmids encoding spike gene 
using PEI under optimized conditions and cultured at 37°C or 32°C. CHO cultures 
were fed every two days with 5% v/v EfficientFeed B. (A) Viable cell density and (B) 
cell viability post-transfection (>70%). (C) IVCD, recombinant qP and purified spike 
 














titer, quantified using Bradford assay. We note that quantification using the A280 
method produced ~25% higher titers. (D) Coomassie-stained reducing SDS-PAGE gel 
of purified HEK and CHO cell-derived spike (~200 kDa) based on the improved 


















Figure 2. Development of a stable production platform for SARS-CoV-2 spike in 
CHO cells. (A) Generation and analysis of CHO stable transfectant pools expressing 
recombinant spike under the control of synthetic promoters. CHO-S cells were 
electroporated in duplicate with plasmids containing a GS gene driven by an SV40 
promoter and a spike gene driven by either a 40RPU or 100RPU synthetic promoter, 
followed by selection in glutamine-free media containing 25 μM or 50 μM MSX 
under suspension condition. Recovered cell pools were assessed for their ability to 
express spike in a 3-days batch culture by Western blot. Figure shown is a 
representative Western blot of two technical replicates. (B) Cells from the best 
performing pools in A were inoculated and cultured at 37°C, 32°C, or 37°C with a 
shift to 32°C at Day 3. Cultures were fed every two days with 5% v/v EfficientFeed 
B. (C) Comparison of the fed-batch culture production performance without or with a 
chemical addition (chemical screening data is shown in Supplementary Figure S4). 1 
mM VPA and/or 12.5 mM betaine were added at Day 4 for the biphasic cultures or at 
Day 6 for the 32°C cultures. Purified spike titer was quantified using Bradford assay. 
Data are normalized with respect to culture at 37°C without any chemical addition. 
Data shown are the mean value ± standard deviation of two independently generated 
stable pools each performed in duplicate. 
 































Figure 3. Optimization of affinity chromatography purification strategies for spike 
protein using HisTrap columns. (A) Coomassie stained gel of the initial purification 
strategy of spike utilizing the method from Stadlbauer et al. (2020) with associated 
impurities identified using tandem mass spectrometry. (B) Assessment of spike 
sample shown in A by Western Blot. (C) Gradient elution of spike protein starting 
from 10 mM imidazole up to a final concentration of 250 mM imidazole. Lanes 1‒6: 
115 mM, 125 mM, 135 mM, 145 mM, 180 mM and 190 mM imidazole, respectively. 
(D) Purified spike from optimized step elution affinity chromatography. 
 
 














Figure 4. Evaluation of CHO-spike anti-SARS-CoV-2 ELISA. (A) 234 negative 
serum samples (taken pre-COVID-19 outbreak) and 26 positive serum samples (taken 
≥15 days post-positive PCR test) were used to evaluate the assay performance, 
yielding an overall sensitivity of 92.3% anti-SARS-CoV-2 antibodies. (B) To 
determine the assay precision, one serum sample was assayed in triplicates at five 
separate times over two days (n = 15). 
 
